Contents:
View analysts price targets for KMPH or view top-rated stocks among Wall Street analysts. According to the issued ratings of 4 analysts in the last year, the consensus rating for Zevra Therapeutics stock is Buy based on the current 4 buy ratings for KMPH. The average twelve-month price prediction for Zevra Therapeutics is $17.25 with a high price target of $20.00 and a low price target of $10.00. KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
Next generation Vande Bharat trains will be able to attain maximum speed of 200 kmph: Railway Minister Ash – Economic Times
Next generation Vande Bharat trains will be able to attain maximum speed of 200 kmph: Railway Minister Ash.
Posted: Tue, 04 Oct 2022 07:00:00 GMT [source]
In Charlotte’s largest labor demonstration in two decades, about 450 American Airlines pilots protested the slow pace of contract talks near an entrance to Charlotte Douglas International Airport on Monday. All values as of most recently reported quarter unless otherwise noted. Please log in to your account or sign up in order to add this asset to your watchlist.
Zevra Therapeutics has received no research coverage in the past 90 days. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Below are the latest news stories about KEMPHARM INC that investors may wish to consider to help them evaluate KMPH as an investment opportunity. The 4 year net income to common stockholders growth rate now stands at 39.86%. Featured in The Global Fintech Index 2020 as the top Fintech company of the country. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.
Kromek Group plc was incorporated in 2013 and is headquartered in Sedgefield, the United Kingdom. Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use di… Real-time analyst ratings, insider transactions, earnings data, and more.
KemPharm to Report Third Quarter 2022 Financial Results
Here are some key insights as we drill into the specifics of these quality attributes.KMPH has a Quality Grade of B, ranking ahead of 90.29% of graded US stocks. Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat’s FREE daily newsletter. KemPharm advancing multicenter Phase 2 clinical trial investigating the efficacy and safety of KP1077 for the treatment of idiopathic hypersomnia KemPharm advancing multicenter Phase 2 clinical t… JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability – yield is subject to change.
By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Only 1 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Zevra Therapeutics does not have a long track record of dividend growth. There is no current short interest data available for KMPH.
According to analysts’ consensus price target of $17.25, Zevra Therapeutics has a forecasted upside of ∞ from its current price of $0.00. Shares of KemPharm Inc. shot up 13% in premarket trade Monday after the specialty pharmaceutical company said a trial of its treatment of ADHD in patients between the ages of 6 and 12 met primary and secondary eff… To see all exchange delays and terms of use, please see disclaimer. In terms of twelve month growth in earnings before interest and taxes, KEMPHARM INC is reporting a growth rate of 282.34%; that’s higher than 94.26% of US stocks. Analysts like Zevra Therapeutics more than other Medical companies. The consensus rating score for Zevra Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.65.
KemPharm (KMPH) Stock: Biotech Short Squeeze, Reality To Set In – Seeking Alpha
KemPharm (KMPH) Stock: Biotech Short Squeeze, Reality To Set In.
Posted: Fri, 05 Mar 2021 08:00:00 GMT [source]
StockInvest.us is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon StockInvest.us. By using the site you agree and are held liable for your own investment decisions and agree to the Terms of Use and Privacy Policy.Please read the full disclaimer here. Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC.
Zevra Therapeutics to Present at 35th Annual Roth Conference
Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303… © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Zevra Therapeutics has received a consensus rating of Buy.
Reuters, the https://1investing.in/ and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers. Aclaris saw its shares surge in the last session with trading volume being higher than average.
KemPharm’s stock soars after ADHD drug trial meets primary endpoints
You can find your newly purchased KemPharm stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets. Discuss news and analysts’ price predictions with the investor community. Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts. Journey Medical Corporation delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Get MarketBeat All Access Free for 30 DaysJoin thousands of other investors who make better investing decisions with our premium tools.
- Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.
- Shares of Aytu BioScience Inc. plummeted 33% and of KemPharm Inc. plunged 32% Friday, to pace the Nasdaq’s decliners, as both specialty pharmaceutical companies announced relatively large public share offerings that pric…
4 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Zevra Therapeutics in the last twelve months. The consensus among Wall Street analysts is that investors should “buy” KMPH shares. 4 analysts have issued 12-month price targets for Zevra Therapeutics’ stock. Their KMPH share price forecasts range from $10.00 to $20.00. On average, they expect the company’s share price to reach $17.25 in the next twelve months.
When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“). Sign-up to receive the latest news and ratings for Kromek Group and its competitors with MarketBeat’s FREE daily newsletter. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.
About Kromek Group (LON:KMK) Stock
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology. For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more. Provides a general description of the business conducted by this company. Three clinical studies demonstrated serdexmethylphenidate , KemPharm’s prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related… Once again, a South Korean artist has come close to topping the Billboard 200 chart in America, only to miss out by one frustrating space.
The latest trend in earnings estimate revisions could translate into further price increase in the… Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months. Shares of Aytu BioScience Inc. plummeted 33% and of KemPharm Inc. plunged 32% Friday, to pace the Nasdaq’s decliners, as both specialty pharmaceutical companies announced relatively large public share offerings that pric… The Company offers discovery and development of therapies for the treatment of attention deficit hyperactivity disorder , pain, and cardiovascular diseases. According to one analyst, the rating for ZVRA stock is “Strong Buy” and the 12-month stock price forecast is $12.0. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries.
KMPH Analyst Ratings By Month
In the past three months, Zevra Therapeutics insiders have not sold or bought any company stock. Here’s what you need to know to navigate the markets today. NAII, ACUR, and EGRX are the stocks whose asset turnover ratios are most correlated with KMPH. KMPH’s price/sales ratio is 17.7; this is 254% higher than that of the median Healthcare stock. Stocks with similar financial metrics, market capitalization, and price volatility to KEMPHARM INC are IPA, VMAR, ONTO, AUR, and SESN. With a year-over-year growth in debt of 750.57%, KEMPHARM INC’s debt growth rate surpasses 97.4% of about US stocks.
For those looking to bet against the upward trend our AI how to calculate a business operating monthly paired with our deep learning algorithms have identified several Top Shorts today. Live from Hong Kong, bringing you the most important global business and breaking markets news information as it happens. KemPharm Inc. shares plummeted in the extended session Thursday after a Food and Drug Administration advisory committee did not recommend that abuse-deterrent labeling be added to the drug maker’s painkiller. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength.
The chart below shows how a company’s share price and consensus price target have changed over time. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA. Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. In addition, the company provides medical imaging products, including CZT gamma detectors for SPECT imaging, CZT bone mineral densitometry detectors, and photon-counting spectral CT systems. It sells its products through distributors, OEMs, and direct sales.
The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs.
Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. See Jiko U.S. Treasuries Risk Disclosures for further details. U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information.
Kromek Group’s stock was trading at GBX 11.15 at the beginning of the year. Since then, KMK shares have decreased by 40.8% and is now trading at GBX 6.60. KMPH’s revenue has moved down $17,673,000 over the prior 15 months.The table below shows KMPH’s growth in key financial areas . Revenue growth over the past 12 months for KEMPHARM INC comes in at -62.3%, a number that bests only 3.08% of the US stocks we’re tracking. An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted.
Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more. Get MarketBeat All Access Free for 30 DaysJoin thousands of other investors who make better investing decisions with our premium tools. Access advanced stock screeners, portfolio monitoring tools, proprietary research reports, and more.
Barchart is committed to ensuring digital accessibility for individuals with disabilities. We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests. KemPharm reports positive top line from a study evaluating serdexmethylphenidate for cardiovascular safety to progress the development of its prodrug KP1077. Realtime quote and/or trades are not sourced from all markets. One share of KMK stock can currently be purchased for approximately GBX 6.60.
